BtBs seminar - Targeting of G protein-coupled receptors (GPCRs) V2R and CaSR for treating Autosomal Dominant Polycystic Kidney Disease.

-
Annarita Di Mise, Department of Biotechnology and Biosciences - University of Milano-Bicocca - Thursday 3 October 2024, 4:30 pm, U3-BIOS building, room U3-08

Seminar - Biotechnology and Biosciences - Thursday 3 October 2024, 4:30 pm, U3-BIOS building, room U3-08

Annarita Di Mise, Department of Biotechnology and Biosciences - University of Milano-Bicocca

Abstract

Image
Seminari-BtBs-UNIMIB

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is an inherited disorder characterized by development and growth of renal cysts, leading to kidney failure. Reduced resting cytosolic calcium and increased cAMP levels are two central defects in ADPKD. The only approved drug able to delay disease progression is the vasopressin receptor 2 (V2R) antagonist Tolvaptan, which has been reported to cause liver toxicity. Co-targeting two GPCRs, the Calcium Sensing Receptor (CaSR) and the V2R, using calcimimetics (CaSR modulators) in combination with vaptans (V2R antagonists), might represent a new application for two existing drugs which may potentiate each other and, more importantly, can be used at lower concentration to limit side effects.

for information:  infobtbs@unimib.it


search:  #DiMiseLab_BtBs  ,  #BtBsSeminar  ,   #BtBsUNIMIB  ,  #BtBsSeminars

Argomento